Crossmark

Remdesivir for COVID-19 and acute kidney injury: disproportionality analysis of data from the U.S. Food and Drug Administration Adverse Event Reporting System

Crossref DOI link: https://doi.org/10.1007/s11096-023-01554-4

Published Online: 2023-03-24

Published Print: 2023-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Li, Xiaotong

Zhou, Liyuan

Gaggl, Martina

Kinlaw, Alan C.

Gou, Zhuoyue

Xu, Yang

Wei, Jingkai

Wang, Tiansheng https://orcid.org/0000-0002-0980-8896
License Information

Text and Data Mining valid from 2023-03-24

Version of Record valid from 2023-03-24
More Information

Article History

Received: 2 June 2022

Accepted: 10 February 2023

First Online: 24 March 2023

Conflicts of interest

: The authors have no conflicts of interest to declare.

Free to read: This content has been made available to all.

Document is current

Any future updates will be listed below